Equillium, Inc. (EQ)
Nasdaq · Healthcare · Biotechnology
$1.45+2.84%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $91.9M
- 52-week range
- $0.76 – $3.54
- 52-week change
- −2.68%
- EPS (trailing)
- −$0.14
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$22.4M
- Diluted EPS
- −$0.39
- Free cash flow
- −$22.8M
From the company’s annual report on SEC EDGAR.
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Headquarters: La Jolla, United States · 14 employees · equilliumbio.com